Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 803

1.

Prevalence of pretreatment and acquired HIV-1 mutations associated with resistance to lamivudine or rilpivirine: a systematic review.

Vannappagari V, Ragone L, Henegar C, van Wyk J, Brown D, Demarest J, Quercia R, St Clair M, Underwood M, Gatell JM, de Ruiter A, Aboud M.

Antivir Ther. 2019 Sep 10. doi: 10.3851/IMP3331. [Epub ahead of print]

PMID:
31503008
2.

Improving the evidence for indicator condition guided HIV testing in Europe: Results from the HIDES II Study - 2012 - 2015.

Raben D, Sullivan AK, Mocroft A, Kutsyna G, Hadžiosmanović V, Vassilenko A, Chkhartisvili N, Mitsura V, Pedersen C, Anderson J, Begovac J, Bak Dragsted U, Bertisch B, Grzeszczuk A, Minton J, Necsoi VC, Kitchen M, Ajana F, Sokhan A, Comi L, Farazmand P, Pesut D, De Wit S, Gatell JM, Gazzard B, d'Arminio Monforte A, Rockstroh JK, Yazdanpanah Y, Champenois K, Jakobsen ML, Lundgren JD; HIDES Study Group.

PLoS One. 2019 Aug 13;14(8):e0220108. doi: 10.1371/journal.pone.0220108. eCollection 2019.

3.

Prevalence, clinical characteristics and outcome of severe primary HIV-1 infection: A prospective cohort study.

Nicolás D, Suárez A, Ambrosioni J, Manzardo C, Ligero C, Costa J, Fernández E, Marcos MÁ, Plana M, Mosquera MM, Sánchez-Palomino S, Gatell JM, Miró JM; Hospital Clinic PHI investigators.

Int J Infect Dis. 2019 Aug 8;88:73-79. doi: 10.1016/j.ijid.2019.08.001. [Epub ahead of print]

4.

Doravirine dose selection and 96-week safety and efficacy versus efavirenz in antiretroviral therapy-naive adults with HIV-1 infection in a Phase IIb trial.

Gatell JM, Morales-Ramirez JO, Hagins DP, Thompson M, Arastéh K, Hoffmann C, Raffi F, Osiyemi O, Dretler R, Harvey C, Xu X, Plettenberg A, Smith DE, Portilla J, Rugina S, Kumar S, Frobose C, Wan H, Rodgers A, Hwang C, Teppler H.

Antivir Ther. 2019 Jun 29. doi: 10.3851/IMP3323. [Epub ahead of print]

PMID:
31355775
5.

Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1.

Eron JJ, Orkin C, Cunningham D, Pulido F, Post FA, De Wit S, Lathouwers E, Hufkens V, Jezorwski J, Petrovic R, Brown K, Van Landuyt E, Opsomer M; EMERALD study group.

Antiviral Res. 2019 Oct;170:104543. doi: 10.1016/j.antiviral.2019.104543. Epub 2019 Jul 4.

6.

iHIVARNA phase IIa, a randomized, placebo-controlled, double-blinded trial to evaluate the safety and immunogenicity of iHIVARNA-01 in chronically HIV-infected patients under stable combined antiretroviral therapy.

de Jong W, Aerts J, Allard S, Brander C, Buyze J, Florence E, van Gorp E, Vanham G, Leal L, Mothe B, Thielemans K, Plana M, Garcia F, Gruters R; iHIVARNA consortium.

Trials. 2019 Jun 17;20(1):361. doi: 10.1186/s13063-019-3409-1.

7.

Metabolic, mitochondrial, renal and hepatic safety of enfuvirtide and raltegravir antiretroviral administration: Randomized crossover clinical trial in healthy volunteers.

Barroso S, Morén C, González-Segura À, Riba N, Arnaiz JA, Manriquez M, Santana G, Blanco JL, Larousse M, Loncà M, Lazzari E, Llopis J, Mallolas J, Miró O, Carné X, Gatell JM, Garrabou G, Martínez E.

PLoS One. 2019 May 23;14(5):e0216712. doi: 10.1371/journal.pone.0216712. eCollection 2019.

8.

Guiding the humoral response against HIV-1 toward a MPER adjacent region by immunization with a VLP-formulated antibody-selected envelope variant.

Beltran-Pavez C, Ferreira CB, Merino-Mansilla A, Fabra-Garcia A, Casadella M, Noguera-Julian M, Paredes R, Olvera A, Haro I, Brander C, Garcia F, Gatell JM, Yuste E, Sanchez-Merino V.

PLoS One. 2018 Dec 19;13(12):e0208345. doi: 10.1371/journal.pone.0208345. eCollection 2018.

9.

Epidemiological changes of acute/recent human immunodeficiency virus type 1 infection in Barcelona, Spain (1997-2015): a prospective cohort study.

Nicolás D, Ambrosioni J, de Lazzari E, Suarez A, Manzardo C, Agüero F, Mosquera MM, Costa J, Ligero C, Marcos MÁ, Sánchez-Palomino S, Fernández E, Plana M, Yerly S, Gatell JM, Miró JM; Hospital Clinic Acute/Recent HIV Study Group.

Clin Microbiol Infect. 2019 Jul;25(7):878-884. doi: 10.1016/j.cmi.2018.10.021. Epub 2018 Nov 22.

PMID:
30472421
10.

Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials.

Cahn P, Madero JS, Arribas JR, Antinori A, Ortiz R, Clarke AE, Hung CC, Rockstroh JK, Girard PM, Sievers J, Man C, Currie A, Underwood M, Tenorio AR, Pappa K, Wynne B, Fettiplace A, Gartland M, Aboud M, Smith K; GEMINI Study Team.

Lancet. 2019 Jan 12;393(10167):143-155. doi: 10.1016/S0140-6736(18)32462-0. Epub 2018 Nov 9. Erratum in: Lancet. 2018 Nov 28;:.

PMID:
30420123
11.

Phase I clinical trial of an intranodally administered mRNA-based therapeutic vaccine against HIV-1 infection.

Leal L, Guardo AC, Morón-López S, Salgado M, Mothe B, Heirman C, Pannus P, Vanham G, van den Ham HJ, Gruters R, Andeweg A, Van Meirvenne S, Pich J, Arnaiz JA, Gatell JM, Brander C, Thielemans K, Martínez-Picado J, Plana M, García F; iHIVARNA consortium.

AIDS. 2018 Nov 13;32(17):2533-2545. doi: 10.1097/QAD.0000000000002026. Erratum in: AIDS. 2019 Oct 1;33(12):1957.

12.

Cholesterol efflux responds to viral load and CD4 counts in HIV+ patients and is dampened in HIV exposed.

Tort O, Escribà T, Egaña-Gorroño L, de Lazzari E, Cofan M, Fernandez E, Gatell JM, Martinez E, Garcia F, Arnedo M.

J Lipid Res. 2018 Nov;59(11):2108-2115. doi: 10.1194/jlr.M088153. Epub 2018 Sep 13.

13.

Individual patient data meta-analysis of randomized controlled trials of dual therapy with a boosted PI plus lamivudine for maintenance of virological suppression: GeSIDA study 9717.

Perez-Molina JA, Pulido F, Di Giambenedetto S, Ribera E, Moreno S, Zamora J, Coscia C, Alejos B, Pitch J, Gatell JM, De Luca A, Arribas JR.

J Antimicrob Chemother. 2018 Nov 1;73(11):2927-2935. doi: 10.1093/jac/dky299.

PMID:
30085184
14.

Direct-acting antivirals are effective and safe in HCV/HIV-coinfected liver transplant recipients who experience recurrence of hepatitis C: A prospective nationwide cohort study.

Manzardo C, Londoño MC, Castells L, Testillano M, Luis Montero J, Peñafiel J, Subirana M, Moreno A, Aguilera V, Luisa González-Diéguez M, Calvo-Pulido J, Xiol X, Salcedo M, Cuervas-Mons V, Manuel Sousa J, Suarez F, Serrano T, Ignacio Herrero J, Jiménez M, Fernandez JR, Giménez C, Del Campo S, Esteban-Mur JI, Crespo G, Moreno A, de la Rosa G, Rimola A, Miro JM; FIPSE LT-HIV investigators.

Am J Transplant. 2018 Oct;18(10):2513-2522. doi: 10.1111/ajt.14996. Epub 2018 Aug 13. Erratum in: Am J Transplant. 2019 Feb;19(2):614.

15.

Immediate Versus Deferred Switching From a Boosted Protease Inhibitor-based Regimen to a Dolutegravir-based Regimen in Virologically Suppressed Patients With High Cardiovascular Risk or Age ≥50 Years: Final 96-Week Results of the NEAT022 Study.

Gatell JM, Assoumou L, Moyle G, Waters L, Johnson M, Domingo P, Fox J, Martinez E, Stellbrink HJ, Guaraldi G, Masia M, Gompels M, De Wit S, Florence E, Esser S, Raffi F, Stephan C, Rockstroh J, Giacomelli A, Vera J, Bernardino JI, Winston A, Saumoy M, Gras J, Katlama C, Pozniak AL; European Network for AIDS Treatment 022 (NEAT022) Study Group .

Clin Infect Dis. 2019 Feb 1;68(4):597-606. doi: 10.1093/cid/ciy505.

PMID:
29912307
16.

Analysis of the costs and cost-effectiveness of the guidelines recommended by the 2018 GESIDA/Spanish National AIDS Plan for initial antiretroviral therapy in HIV-infected adults.

Pérez-Molina JA, Martínez E, Blasco AJ, Arribas JR, Domingo P, Iribarren JA, Knobel H, Lázaro P, López-Aldeguer J, Lozano F, Mariño A, Miró JM, Moreno S, Negredo E, Pulido F, Rubio R, Santos J, de la Torre J, Tuset M, von Wichmann MA, Gatell JM.

Enferm Infecc Microbiol Clin. 2019 Mar;37(3):151-159. doi: 10.1016/j.eimc.2018.04.010. Epub 2018 Jun 6. English, Spanish.

PMID:
29884455
17.

Executive summary of the GeSIDA/National AIDS Plan consensus document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2018).

AIDS Study Group (GeSIDA) of the Spanish Society of Infectious Diseases and Clinical Microbiology and the National AIDS Plan:.

Enferm Infecc Microbiol Clin. 2019 Mar;37(3):195-202. doi: 10.1016/j.eimc.2018.02.010. Epub 2018 Jun 18. English, Spanish.

PMID:
29759422
18.

Using Clinical Research Networks to Assess Severity of an Emerging Influenza Pandemic.

Simonsen L, Higgs E, Taylor RJ, Wentworth D, Cozzi-Lepri A, Pett S, Dwyer DE, Davey R, Lynfield R, Losso M, Morales K, Glesby MJ, Weckx J, Carey D, Lane C, Lundgren J; INSIGHT FLU002 and FLU003 Study Groups.

Clin Infect Dis. 2018 Jul 18;67(3):341-349. doi: 10.1093/cid/ciy088.

19.

A maintenance 3-day-per-week schedule with the single tablet regimen efavirenz/emtricitabine/tenofovir disoproxil fumarate is effective and decreases sub-clinical toxicity.

Rojas J, Blanco JL, Sanchez-Palomino S, Marcos MA, Guardo AC, Gonzalez-Cordon A, Lonca M, Tricas A, Rodriguez A, Romero A, Miro JM, Mallolas J, Gatell JM, Plana M, Martinez E.

AIDS. 2018 Jul 31;32(12):1633-1641. doi: 10.1097/QAD.0000000000001843.

PMID:
29746294
20.

Subclinical cardiovascular disease in patients starting contemporary protease inhibitors.

González-Cordón A, Doménech M, Camafort M, Martínez-Rebollar M, Torres B, Laguno M, Rojas J, Loncà M, Blanco JL, Mallolas J, Gatell JM, de Lazzari E, Martínez E.

HIV Med. 2018 May 10. doi: 10.1111/hiv.12619. [Epub ahead of print]

PMID:
29745457
21.

Increased cholesterol absorption rather than synthesis is involved in boosted protease inhibitor-associated hypercholesterolaemia.

Leyes P, Cofan M, González-Cordón A, de Lazzari E, Trabal J, Domingo P, Negredo E, Vidal F, Forga MT, Gatell JM, Ros E, Martínez E.

AIDS. 2018 Jun 19;32(10):1309-1316. doi: 10.1097/QAD.0000000000001837.

PMID:
29683854
22.

Correction: Safety and vaccine-induced HIV-1 immune responses in healthy volunteers following a late MVA-B boost 4 years after the last immunization.

Guardo AC, Gómez CE, Díaz-Brito V, Pich J, Arnaiz JA, Perdiguero B, García-Arriaza J, González N, Sorzano COS, Jiménez L, Jiménez JL, Muñoz-Fernández MÁ, Gatell JM, Alcamí J, Esteban M, de Quirós JCLB, García F, Plana M; RISVAC02boost study.

PLoS One. 2018 Apr 10;13(4):e0195915. doi: 10.1371/journal.pone.0195915. eCollection 2018.

23.

Dolutegravir-based maintenance monotherapy versus dual therapy with lamivudine: a planned 24 week analysis of the DOLAM randomized clinical trial.

Blanco JL, Rojas J, Paredes R, Negredo E, Mallolas J, Casadella M, Clotet B, Gatell JM, de Lazzari E, Martinez E; DOLAM Study Team.

J Antimicrob Chemother. 2018 Jul 1;73(7):1965-1971. doi: 10.1093/jac/dky093.

PMID:
29608685
24.

Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial.

Molina JM, Squires K, Sax PE, Cahn P, Lombaard J, DeJesus E, Lai MT, Xu X, Rodgers A, Lupinacci L, Kumar S, Sklar P, Nguyen BY, Hanna GJ, Hwang C; DRIVE-FORWARD Study Group.

Lancet HIV. 2018 May;5(5):e211-e220. doi: 10.1016/S2352-3018(18)30021-3. Epub 2018 Mar 25.

PMID:
29592840
25.

Gender differences in the use of cardiovascular interventions in HIV-positive persons; the D:A:D Study.

Hatleberg CI, Ryom L, El-Sadr W, Mocroft A, Reiss P, De Wit S, Dabis F, Pradier C, d'Arminio Monforte A, Kovari H, Law M, Lundgren JD, Sabin CA; Data Collection of Adverse Events of Anti-HIV drugs (D:A:D) Study group.

J Int AIDS Soc. 2018 Mar;21(3). doi: 10.1002/jia2.25083.

26.

Highlights of the 2017 European AIDS Clinical Society (EACS) Guidelines for the treatment of adult HIV-positive persons version 9.0.

Ryom L, Boesecke C, Bracchi M, Ambrosioni J, Pozniak A, Arribas J, Behrens G, Mallon P, Puoti M, Rauch A, Miro JM, Kirk O, Marzolini C, Lundgren JD, Battegay M; EACS Governing Board.

HIV Med. 2018 May;19(5):309-315. doi: 10.1111/hiv.12600. Epub 2018 Mar 1.

27.

Long-term effectiveness of recommended boosted protease inhibitor-based antiretroviral therapy in Europe.

Santos JR, Cozzi-Lepri A, Phillips A, De Wit S, Pedersen C, Reiss P, Blaxhult A, Lazzarin A, Sluzhynska M, Orkin C, Duvivier C, Bogner J, Gargalianos-Kakolyris P, Schmid P, Hassoun G, Khromova I, Beniowski M, Hadziosmanovic V, Sedlacek D, Paredes R, Lundgren JD; EuroSIDA study group.

HIV Med. 2018 May;19(5):324-338. doi: 10.1111/hiv.12581. Epub 2018 Feb 1.

PMID:
29388732
28.

Abacavir usage patterns and hypersensitivity reactions in the EuroSIDA cohort.

Roen A, Laut K, Pelchen-Matthews A, Borodulina E, Caldeira L, Clarke A, Clotet B, d'Arminio Monforte A, Fätkenheuer G, Gatell Artigas JM, Karpov I, Kuznetsova A, Kyselyova G, Mozer-Lisewska I, Mulcahy F, Ragone L, Scherrer A, Uzdaviniene V, Vandekerckhove L, Vannappagari V, Ostergaard L, Mocroft A; EuroSIDA study.

HIV Med. 2018 Apr;19(4):252-260. doi: 10.1111/hiv.12573. Epub 2017 Dec 22.

PMID:
29271606
29.

Promoting high standards of care for women living with HIV: position statement from the Women Against Viruses in Europe Working Group.

Kowalska JD, Aebi-Popp K, Loutfy M, Post FA, Perez-Elias MJ, Johnson M, Mulcahy F; Women Against Viruses in Europe (WAVE) Working Group.

HIV Med. 2018 Feb;19(2):167-173. doi: 10.1111/hiv.12565. Epub 2017 Nov 21. Review.

PMID:
29159861
30.

Loading dendritic cells with gold nanoparticles (GNPs) bearing HIV-peptides and mannosides enhance HIV-specific T cell responses.

Climent N, García I, Marradi M, Chiodo F, Miralles L, Maleno MJ, Gatell JM, García F, Penadés S, Plana M.

Nanomedicine. 2018 Feb;14(2):339-351. doi: 10.1016/j.nano.2017.11.009. Epub 2017 Nov 20.

PMID:
29157976
31.

[Polypharmacy and potential drug-drug interactions in an HIV-infected elderly population].

Bastida C, Grau A, Márquez M, Tuset M, De Lazzari E, Martínez E, Gatell JM.

Farm Hosp. 2017 Nov 1;41(6):700. doi: 10.7399/fh.10890. Spanish. No abstract available.

32.

Switching from a ritonavir-boosted protease inhibitor to a dolutegravir-based regimen for maintenance of HIV viral suppression in patients with high cardiovascular risk.

Gatell JM, Assoumou L, Moyle G, Waters L, Johnson M, Domingo P, Fox J, Martinez E, Stellbrink HJ, Guaraldi G, Masia M, Gompels M, De Wit S, Florence E, Esser S, Raffi F, Pozniak AL; NEAT022 Study Group*.

AIDS. 2017 Nov 28;31(18):2503-2514. doi: 10.1097/QAD.0000000000001675.

33.

Tenofovir disoproxil fumarate/emtricitabine plus ritonavir-boosted lopinavir or cobicistat-boosted elvitegravir as a single-tablet regimen for HIV post-exposure prophylaxis.

Inciarte A, Leal L, González E, León A, Lucero C, Mallolas J, Torres B, Laguno M, Rojas J, Martínez-Rebollar M, González-Cordón A, Cruceta A, Arnaiz JA, Gatell JM, García F; STRIBPEP Study Group.

J Antimicrob Chemother. 2017 Oct 1;72(10):2857-2861. doi: 10.1093/jac/dkx246.

PMID:
29091217
34.

Prosthetic Valve Candida spp. Endocarditis: New Insights Into Long-term Prognosis-The ESCAPE Study.

Rivoisy C, Vena A, Schaeffer L, Charlier C, Fontanet A, Delahaye F, Bouza E, Lortholary O, Munoz P, Lefort A; French Mycoses Study Group and Grupo de Apoyo al Manejo de las Endocarditis en España (GAMES).

Clin Infect Dis. 2018 Mar 5;66(6):825-832. doi: 10.1093/cid/cix913.

PMID:
29077791
35.

Safety and vaccine-induced HIV-1 immune responses in healthy volunteers following a late MVA-B boost 4 years after the last immunization.

Guardo AC, Gómez CE, Díaz-Brito V, Pich J, Arnaiz JA, Perdiguero B, García-Arriaza J, González N, Sorzano COS, Jiménez L, Jiménez JL, Muñoz-Fernández MÁ, Gatell JM, Alcamí J, Esteban M, López Bernaldo de Quirós JC, García F, Plana M; RISVAC02boost study.

PLoS One. 2017 Oct 24;12(10):e0186602. doi: 10.1371/journal.pone.0186602. eCollection 2017. Erratum in: PLoS One. 2018 Apr 10;13(4):e0195915.

36.

Dual Therapy With Darunavir and Ritonavir Plus Lamivudine vs Triple Therapy With Darunavir and Ritonavir Plus Tenofovir Disoproxil Fumarate and Emtricitabine or Abacavir and Lamivudine for Maintenance of Human Immunodeficiency Virus Type 1 Viral Suppression: Randomized, Open-Label, Noninferiority DUAL-GESIDA 8014-RIS-EST45 Trial.

Pulido F, Ribera E, Lagarde M, Pérez-Valero I, Palacios R, Iribarren JA, Payeras A, Domingo P, Sanz J, Cervero M, Curran A, Rodríguez-Gómez FJ, Téllez MJ, Ryan P, Barrufet P, Knobel H, Rivero A, Alejos B, Yllescas M, Arribas JR; DUAL-GESIDA-8014-RIS-EST45 Study Group.

Clin Infect Dis. 2017 Nov 29;65(12):2112-2118. doi: 10.1093/cid/cix734.

PMID:
29020293
37.

Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial.

Orkin C, Molina JM, Negredo E, Arribas JR, Gathe J, Eron JJ, Van Landuyt E, Lathouwers E, Hufkens V, Petrovic R, Vanveggel S, Opsomer M; EMERALD study group.

Lancet HIV. 2018 Jan;5(1):e23-e34. doi: 10.1016/S2352-3018(17)30179-0. Epub 2017 Oct 6.

PMID:
28993180
38.

Incidence of cancer and overall risk of mortality in individuals treated with raltegravir-based and non-raltegravir-based combination antiretroviral therapy regimens.

Cozzi-Lepri A, Zangerle R, Machala L, Zilmer K, Ristola M, Pradier C, Kirk O, Sambatakou H, Fätkenheuer G, Yust I, Schmid P, Gottfredsson M, Khromova I, Jilich D, Flisiak R, Smidt J, Rozentale B, Radoi R, Losso MH, Lundgren JD, Mocroft A; EuroSIDA Study Group.

HIV Med. 2018 Feb;19(2):102-117. doi: 10.1111/hiv.12557. Epub 2017 Oct 6.

39.

Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial.

Cahn P, Kaplan R, Sax PE, Squires K, Molina JM, Avihingsanon A, Ratanasuwan W, Rojas E, Rassool M, Bloch M, Vandekerckhove L, Ruane P, Yazdanpanah Y, Katlama C, Xu X, Rodgers A, East L, Wenning L, Rawlins S, Homony B, Sklar P, Nguyen BY, Leavitt R, Teppler H; ONCEMRK Study Group.

Lancet HIV. 2017 Nov;4(11):e486-e494. doi: 10.1016/S2352-3018(17)30128-5. Epub 2017 Sep 11.

PMID:
28918877
40.

Imbalance in mitochondrial dynamics and apoptosis in pregnancies among HIV-infected women on HAART with obstetric complications.

Guitart-Mampel M, Hernandez AS, Moren C, Catalan-Garcia M, Tobias E, Gonzalez-Casacuberta I, Juarez-Flores DL, Gatell JM, Cardellach F, Milisenda JC, Grau JM, Gratacos E, Figueras F, Garrabou G.

J Antimicrob Chemother. 2017 Sep 1;72(9):2578-2586. doi: 10.1093/jac/dkx187.

PMID:
28859443
41.

The extent of B-cell activation and dysfunction preceding lymphoma development in HIV-positive people.

Shepherd L, Borges ÁH, Harvey R, Bower M, Grulich A, Silverberg M, Weber J, Ristola M, Viard JP, Bogner JR, Gargalianos-Kakolyris P, Mussini C, Mansinho K, Yust I, Paduta D, Jilich D, Smiatacz T, Radoi R, Tomazic J, Plomgaard P, Frikke-Schmidt R, Lundgren J, Mocroft A; EuroSIDA in EuroCOORD.

HIV Med. 2018 Feb;19(2):90-101. doi: 10.1111/hiv.12546. Epub 2017 Aug 31.

PMID:
28857427
42.

Polypharmacy and potential drug-drug interactions in an HIV-infected elderly population.

Bastida C, Grau A, Márquez M, Tuset M, De Lazzari E, Martínez E, Gatell JM.

Farm Hosp. 2017 Sep 1;41(5):618-624. doi: 10.7399/fh.10778. Erratum in: Farm Hosp. 2017 Nov 01;41(6):700.

43.

Early detection of HIV infection and of asymptomatic sexually transmitted infections among men who have sex with men.

Coll J, Videla S, Leon A, Ornelas A, García F, Fernández E, Blanco JL, Carrillo A, Bravo I, Meulbroek M, García-Cuyas F, González V, Casabona J, Leal L, Clotet B, Brander C; Check-Ear Project.

Clin Microbiol Infect. 2018 May;24(5):540-545. doi: 10.1016/j.cmi.2017.08.012. Epub 2017 Aug 24.

44.

Impact of long-term antiretroviral therapy interruption and resumption on viral reservoir in HIV-1 infected patients.

Montserrat M, Plana M, Guardo AC, Andrés C, Climent N, Gallart T, Leal L, Gatell JM, Sánchez-Palomino S, García F.

AIDS. 2017 Aug 24;31(13):1895-1897. doi: 10.1097/QAD.0000000000001560.

PMID:
28590333
45.

Costs and cost-efficacy analysis of the 2017 GESIDA/Spanish National AIDS Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults.

Rivero A, Pérez-Molina JA, Blasco AJ, Arribas JR, Asensi V, Crespo M, Domingo P, Iribarren JA, Lázaro P, López-Aldeguer J, Lozano F, Martínez E, Moreno S, Palacios R, Pineda JA, Pulido F, Rubio R, Santos J, de la Torre J, Tuset M, Gatell JM.

Enferm Infecc Microbiol Clin. 2018 May;36(5):268-276. doi: 10.1016/j.eimc.2017.04.002. Epub 2017 May 19. English, Spanish.

PMID:
28532596
46.

New challenges in therapeutic vaccines against HIV infection.

Leal L, Lucero C, Gatell JM, Gallart T, Plana M, García F.

Expert Rev Vaccines. 2017 Jun;16(6):587-600. doi: 10.1080/14760584.2017.1322513. Epub 2017 May 4. Review.

PMID:
28431490
47.

Preclinical development of BCG.HIVA2auxo.int, harboring an integrative expression vector, for a HIV-TB Pediatric vaccine. Enhancement of stability and specific HIV-1 T-cell immunity.

Mahant A, Saubi N, Eto Y, Guitart N, Gatell JM, Hanke T, Joseph J.

Hum Vaccin Immunother. 2017 Aug 3;13(8):1798-1810. doi: 10.1080/21645515.2017.1316911. Epub 2017 Apr 20.

48.

Tolerability of integrase inhibitors in a real-life setting.

Peñafiel J, de Lazzari E, Padilla M, Rojas J, Gonzalez-Cordon A, Blanco JL, Blanch J, Marcos MA, Lonca M, Martinez-Rebollar M, Laguno M, Tricas A, Rodriguez A, Mallolas J, Gatell JM, Martinez E.

J Antimicrob Chemother. 2017 Jun 1;72(6):1752-1759. doi: 10.1093/jac/dkx053.

PMID:
28333231
49.

Estimation of renal function by CKD-EPI versus MDRD in a cohort of HIV-infected patients: a cross-sectional analysis.

Cristelli MP, Cofán F, Rico N, Trullàs JC, Manzardo C, Agüero F, Bedini JL, Moreno A, Oppenheimer F, Miro JM; CKD-H. Clinic Investigators.

BMC Nephrol. 2017 Feb 10;18(1):58. doi: 10.1186/s12882-017-0470-4.

50.

Influence of vancomycin minimum inhibitory concentration on the outcome of methicillin-susceptible Staphylococcus aureus left-sided infective endocarditis treated with antistaphylococcal β-lactam antibiotics: a prospective cohort study by the International Collaboration on Endocarditis.

Pericàs JM, Messina JA, Garcia-de-la-Mària C, Park L, Sharma-Kuinkel BK, Marco F, Wray D, Kanafani ZA, Carugati M, Durante-Mangoni E, Tattevin P, Chu VH, Moreno A, Fowler VG Jr, Miró JM; International Collaboration on Endocarditis Microbiology Investigators.

Clin Microbiol Infect. 2017 Aug;23(8):544-549. doi: 10.1016/j.cmi.2017.01.017. Epub 2017 Feb 1.

Supplemental Content

Loading ...
Support Center